Weiqiang Lu
Overview
Explore the profile of Weiqiang Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, et al.
Nat Immunol
. 2025 Mar;
PMID: 40065162
No abstract available.
2.
Wang Y, Abuduaini N, Liu W, Song Y, Ke Z, Wang X, et al.
Genes Dis
. 2025 Feb;
12(3):101356.
PMID: 39926333
No abstract available.
3.
He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, et al.
Nat Immunol
. 2025 Feb;
26(3):391-403.
PMID: 39905201
Most patients with colorectal cancer do not achieve durable clinical benefits from immunotherapy, underscoring the existence of alternative immunosuppressive mechanisms. Here we found that activation of the lactate receptor HCAR1...
4.
Ma Y, Wang Y, Tang M, Weng Y, Chen Y, Xu Y, et al.
Nat Commun
. 2025 Jan;
16(1):605.
PMID: 39799123
G protein-coupled receptor 4 (GPR4) belongs to the subfamily of proton-sensing GPCRs (psGPCRs), which detect pH changes in extracellular environment and regulate diverse physiological responses. GPR4 was found to be...
5.
Cheng Z, Zhang Y, Du L, Wang W, Chai X, He M, et al.
J Med Chem
. 2025 Jan;
68(2):1587-1607.
PMID: 39757828
The development of dual prostaglandin E receptors 2/4 (EP2/EP4) antagonists represents an attractive strategy for cancer immunotherapy. Herein, a series of 4,7-dihydro-5-thieno[2,3-]pyran derivatives with potent EP2/EP4 dual antagonism were discovered...
6.
Xiong D, Qiu Y, Zhao J, Zhou Y, Lee D, Gupta S, et al.
Nat Biotechnol
. 2024 Oct;
PMID: 39448882
To assist the translation of genetic findings to disease pathobiology and therapeutics discovery, we present an ensemble deep learning framework, termed PIONEER (Protein-protein InteractiOn iNtErfacE pRediction), that predicts protein-binding partner-specific...
7.
Lu W, Cui J, Wang W, Hu Q, Xue Y, Liu X, et al.
Nat Commun
. 2024 Jun;
15(1):4703.
PMID: 38830868
Nuclear factor erythroid 2-related factor 2 (NRF2) hyperactivation has been established as an oncogenic driver in a variety of human cancers, including non-small cell lung cancer (NSCLC). However, despite massive...
8.
Guo M, Hu P, Xie J, Tang K, Hu S, Sun J, et al.
Genes Dis
. 2024 Apr;
11(4):101164.
PMID: 38560505
Gastric cancer is highly prevalent among digestive tract tumors. Due to the intricate nature of the gastric cancer immune microenvironment, there is currently no effective treatment available for advanced gastric...
9.
Wang H, Yang X, Li Y, Ze S, Feng B, Weng Y, et al.
J Med Chem
. 2024 Mar;
67(6):5075-5092.
PMID: 38483150
Aberrantly elevated adenosine in the tumor microenvironment exerts its immunosuppressive functions through adenosine receptors AR and AR. Antagonism of AR and AR has the potential to suppress tumor growth. Herein,...
10.
Ling Q, Fu Y, Lou Z, Yue B, Guo C, Hu X, et al.
Adv Sci (Weinh)
. 2024 Mar;
11(21):e2308181.
PMID: 38459671
Developing synthetic molecular devices for controlling ion transmembrane transport is a promising research field in supramolecular chemistry. These artificial ion channels provide models to study ion channel diseases and have...